Syros Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Syros Pharmaceuticals, Inc.
Venus Medtech has agreed a licensing deal with Endoluminal Sciences, an Australian start-up with technology to prevent paravalvular leakage and improve TAVR outcomes.
Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.
Syros has failed to progress in its leukemia niche since its launch a few years ago, but a new drug candidate and funding could revive its fortunes.
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
Drug Discovery Tools
- Drug Discovery Tools